Several African nations are rejecting health deals offered by the U.S. government due to concerns over data sovereignty and patient privacy. Countries including Ghana, Zimbabwe, and South Africa have pushed back against terms that require sharing pathogen data without guaranteed reciprocal access to the resulting vaccines or treatments.
Data Sovereignty and the Ghanaian Objection
The tension centers on the ownership and control of biological data. In Ghana, the government objected to U.S. offers based on the sheer volume of information requested. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission, told the BBC that the terms created a one-way street for medical intelligence.
“We had concerns around the scope and breadth of data that was being required. It was us generating data and passing it on to the US authorities, and there were no real reciprocal measures when it comes to the protection of Ghanaian data and Ghanaian sovereignty.”
Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission
Kavaarpuo emphasized that the lack of oversight becomes critical the moment information crosses borders, stating that “once the data left the Ghanaian borders, we had no control over what becomes of it.”
This is not an isolated incident. A Kenyan court initially suspended a similar deal following legal challenges that demanded stricter protections for patient privacy.
The ‘Vaccine Gap’ and Zimbabwe’s Rejection
For Zimbabwe, the issue is less about the act of sharing and more about the lack of guaranteed returns. The government rejected a deal because there were no assurances that drugs or vaccines developed from the pathogens would be available to its people.
A government spokesman noted that the World Health Organization (WHO) already had a system for members to share data and benefit from any treatments in future pandemics. By bypassing this established framework in favor of a bilateral U.S. deal, Zimbabwe viewed the arrangement as an unacceptable risk.
The historical context of the COVID-19 pandemic looms large over these negotiations. Many African nations viewed the race for a vaccine as a cautionary tale where the continent’s pathogen data was utilized globally, yet the people themselves struggled to secure doses.
Transactional Leverage vs. Altruism
The U.S. State Department maintains that the requested materials are “aggregated and de-identified data” consistent with what has been used for years in infectious disease combat. Historically, African nations shared such information through programs like USAID and Pepfar, America’s main programme to tackle HIV and Aids.
However, the political climate has shifted. Nelson Aghogho Evaborhene, a PhD fellow in global health governance at Roskilde University in Denmark, argues that while the relationship was always unequal, it was previously “tolerable politically” because it could be framed as an altruistic effort to improve health services. Now, he suggests, the dynamic has shifted toward “transactional leverage.”
This shift has galvanized civil society. Aggrey Aluso, executive director of Resilience Action Network Africa (Rana), believes Africa’s strength lies in the “important information” it holds, which is essential for the global health security ecosystem.
Rana joined more than 50 civil society groups in signing an open letter to African leaders, warning that the U.S. terms were not designed with African national or regional interests in mind.
South Africa’s Stance on Pathogen Diplomacy
South Africa has taken an even more confrontational tone regarding the perceived imbalance of these deals. Health Minister Dr Aaron Motsoaledi explicitly questioned the dignity of accepting such terms.
Frankly speaking, no nation on Earth that respects itself should accede to [two requests]. That [the US] will get their pathogen if there’s any pandemic or epidemic in their area. And they’ll also provide them with a genome for life. But the US is going to give them money for five years.
Dr Aaron Motsoaledi, South Africa’s Health Minister
The core of the dispute is a clash between short-term financial incentive and long-term biological sovereignty. The U.S. offers five-year funding windows; the cost is the permanent surrender of genetic data.
The urgency of this debate is heightened by current health crises, including a new outbreak of Ebola in the Democratic Republic of Congo, which puts the theoretical struggle over data rights into a practical, life-and-death context.
The rejection of these deals signals a broader movement toward “health diplomacy” where African nations no longer view themselves as mere providers of raw biological data, but as stakeholders demanding equitable access to the medical breakthroughs that their data makes possible.
